The filing content is cut off before financial statements are presented in full, but there is sufficient substantive disclosure content (cover page data, share count, company identity, filing period, forward-looking statement topics, and balance sheet header) to exceed 150 words of substantive content. I will proceed with what is available.

Caris Life Sciences, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing share count, filer status, and forward-looking risk factors related to its precision medicine operations.

Key Highlights

  • Share count: As of November 2, 2026, the registrant had 286,784,504 shares of common stock, par value $0.001 per share, outstanding, according to the filing.
  • Emerging growth company: The filing indicates Caris Life Sciences qualifies as an emerging growth company under Rule 12b-2 of the Exchange Act.
  • Non-accelerated filer: The registrant identified itself as a non-accelerated filer and is not a smaller reporting company, per the filing.
  • Dual listing noted: The filing lists the common stock as registered on The Nasdaq Stock Market LLC and New York Stock Exchange Texas, both under the trading symbol CAI.
  • Material weakness disclosed: The filing references "remediating the material weakness in our internal control over financial reporting" among the subjects of its forward-looking statements.
  • Reporting period: The quarterly report covers the three-month period ended September 30, 2026, with commission file number 001-42706.

Caris Life Sciences Q3 2026 Filing: Filer Status, Share Count, and Disclosed Risk Areas

Caris Life Sciences, Inc., a Texas-incorporated company headquartered at 750 W. John Carpenter Freeway, Suite 800, Irving, TX 75039, filed a Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, the registrant had 286,784,504 shares of common stock outstanding as of November 2, 2026. The common stock carries a par value of $0.001 per share and is registered on The Nasdaq Stock Market LLC and New York Stock Exchange Texas under the trading symbol CAI (NASDAQ:CAI).

The company disclosed that it qualifies as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act. It is classified as a non-accelerated filer and is not a smaller reporting company or a large accelerated filer, according to the filing. The registrant confirmed it is not a shell company.

The filing's forward-looking statements section identifies a range of risk areas, including third-party payer reimbursement decisions, regulatory requirements, competition in the precision medicine industry, intellectual property matters, and, notably, "remediating the material weakness in our internal control over financial reporting." The company cautioned that these forward-looking statements are subject to risks and uncertainties described in its Annual Report on Form 10-K for the year ended December 31, 2025, and that it undertakes no obligation to update forward-looking statements after the date of the quarterly report. The condensed consolidated financial statements were presented as unaudited.

What Was Disclosed

Caris Life Sciences filed a Form 10-Q for the quarter ended September 30, 2026, reporting 286,784,504 shares outstanding as of November 2, 2026, emerging growth company status, and ongoing remediation of a material weakness in internal controls over financial reporting.